Gossamer Bio, Inc. (NASDAQ:GOSS) Stock Has Average Price Target of $256.00

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) have been assigned a consensus rating of “Hold” from the ten ratings firms that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $256.00.

GOSS has been the topic of several research reports. Chardan Capital restated a “buy” rating on shares of Gossamer Bio in a research report on Monday, October 26th. Leerink Partners raised Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price objective for the company in a research report on Tuesday, July 28th. HC Wainwright restated a “buy” rating on shares of Gossamer Bio in a report on Thursday, August 27th. Weiss Ratings cut shares of Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. Finally, Wall Street Zen downgraded shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th.

Gossamer Bio Price Performance

Shares of NASDAQ:GOSS opened at $9.77 on Monday. The stock’s 50-day moving average is $10.81 and its 200 day moving average is $38.10. The company has a market cap of $59.69 million, a PE ratio of -0.17 and a beta of 2.28. Gossamer Bio has a 1 year low of $8.29 and a 1 year high of $309.60.

Institutional Trading of Gossamer Bio

Several institutional investors have recently added to or reduced their stakes in the business. Corient Private Wealth LP increased its holdings in Gossamer Bio by 41.3% in the 2nd quarter. Corient Private Wealth LP now owns 5,632,698 shares of the company’s stock worth $927,000 after buying an additional 1,647,315 shares in the last quarter. Hsbc Holdings PLC boosted its holdings in shares of Gossamer Bio by 1,289.4% during the 2nd quarter. Hsbc Holdings PLC now owns 1,583,118 shares of the company’s stock valued at $267,000 after acquiring an additional 1,469,175 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Gossamer Bio in the second quarter worth approximately $65,000. Hhlr Advisors LTD. purchased a new position in shares of Gossamer Bio during the second quarter valued at approximately $819,000. Finally, ARCH Venture Management LLC purchased a new position in shares of Gossamer Bio during the second quarter valued at approximately $1,326,004. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders.

Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.